IRAK1 and cancer: Triple-negative breast cancer often shows overexpression of interleukin-1 receptor-associated kinase 1 (IRAK1), and paclitaxel treatment activates IRAK1, which increases the stemness of cancer cells and confers resistance to paclitaxel treatment.